Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions
Paclitaxel-coated balloon (PCB) treatment guided by fractional flow reserve (FFR) is safe and effective for de novo coronary lesions. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits simil...
Gespeichert in:
Veröffentlicht in: | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING 2020-02, Vol.36 (2), p.179-185 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 185 |
---|---|
container_issue | 2 |
container_start_page | 179 |
container_title | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING |
container_volume | 36 |
creator | Chung, Ju-Hyun Shin, Eun-Seok Her, Ae-Young Lee, Joo Myung Doh, Joon-Hyung Nam, Chang-Wook Koo, Bon-Kwon |
description | Paclitaxel-coated balloon (PCB) treatment guided by fractional flow reserve (FFR) is safe and effective for de novo coronary lesions. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR in de novo lesion treatment with PCB. Baseline, post-balloon and 9-month angiographical parameters were obtained from 116 lesions of 104 patients. The cutoff value of iFR after balloon angioplasty used to define functionally nonsignificant residual stenotic lesions was 0.86 and they were subdivided into PCB or Stent group according to the treated device. The primary endpoint was late lumen loss at 9 months and the secondary endpoint was target vessel failure (TVF) at 3 years. Fifty-eight lesions were treated with PCB only and 58 lesions were treated with metal stent implantation. There were no differences in iFR between PCB and Stent groups at baseline (0.76 ± 0.19 vs. 0.73 ± 0.23, p = 0.630) and after procedure (0.93 ± 0.04 vs. 0.94 ± 0.05, p = 0.574). At 9 months, late lumen loss was significantly lower in PCB group compared with Stent group (0.04 ± 0.32 mm vs. 0.59 ± 0.77 mm, p = 0.001). At 3-year follow-up, TVF were not different between the treatment groups (5.2% vs. 8.6%, p = 0.453). PCB treatment guided by iFR measured right after balloon angioplasty is safe and effective for de novo coronary lesions with good angiographic results at 9 months and similar clinical outcomes at 3 years compared to stent group. |
doi_str_mv | 10.1007/s10554-019-01707-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_31598811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2303745521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-bad01641fd678601bdd52c0fb75b9ff339b3117759f326a388a46f77d40769ce3</originalsourceid><addsrcrecordid>eNqNkV2L1TAQhoMo7of-AS-k4I2wRGeSpmkv5eDHwoI3eh3SdLJ06UmOSbqr_94cu67ghQgJCeF5h5k8jL1AeIMA-m1GUKrlgEPdGjRXj9gpKi056FY-Pt67gSs9tCfsLOcbABAg5FN2IlENfY94yugy5GJDXRTX3NzZW-I-ETXJljny63WeaGoO1i1zsd9p4S7aUl9GuywxhqYksmVPoTQ-pmaiJsTb2LiYYrDpR7NQnmPIz9gTb5dMz-_Pc_b1w_svu0_86vPHy927K-6kVoWPdgLsWvRTp_sOcJwmJRz4Uatx8F7KYZSIWqvBS9FZ2fe27bzWUwu6GxzJc_Z6q3tI8dtKuZj9nB0tyzaeERKkbpUSWNFXf6E3cU2hdlcp1XYoAUWlxEa5FHNO5M0hzfs6mUEwRwlmk2CqBPNLglE19PK-9DruaXqI_P71ClxswB2N0Wc3U3D0gFVNCqVALeBorNL9_9O7qqmKC7u4hlKjcovmiodrSn-G_Ef_PwEDVbMG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2354613012</pqid></control><display><type>article</type><title>Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Chung, Ju-Hyun ; Shin, Eun-Seok ; Her, Ae-Young ; Lee, Joo Myung ; Doh, Joon-Hyung ; Nam, Chang-Wook ; Koo, Bon-Kwon</creator><creatorcontrib>Chung, Ju-Hyun ; Shin, Eun-Seok ; Her, Ae-Young ; Lee, Joo Myung ; Doh, Joon-Hyung ; Nam, Chang-Wook ; Koo, Bon-Kwon</creatorcontrib><description>Paclitaxel-coated balloon (PCB) treatment guided by fractional flow reserve (FFR) is safe and effective for de novo coronary lesions. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR in de novo lesion treatment with PCB. Baseline, post-balloon and 9-month angiographical parameters were obtained from 116 lesions of 104 patients. The cutoff value of iFR after balloon angioplasty used to define functionally nonsignificant residual stenotic lesions was 0.86 and they were subdivided into PCB or Stent group according to the treated device. The primary endpoint was late lumen loss at 9 months and the secondary endpoint was target vessel failure (TVF) at 3 years. Fifty-eight lesions were treated with PCB only and 58 lesions were treated with metal stent implantation. There were no differences in iFR between PCB and Stent groups at baseline (0.76 ± 0.19 vs. 0.73 ± 0.23, p = 0.630) and after procedure (0.93 ± 0.04 vs. 0.94 ± 0.05, p = 0.574). At 9 months, late lumen loss was significantly lower in PCB group compared with Stent group (0.04 ± 0.32 mm vs. 0.59 ± 0.77 mm, p = 0.001). At 3-year follow-up, TVF were not different between the treatment groups (5.2% vs. 8.6%, p = 0.453). PCB treatment guided by iFR measured right after balloon angioplasty is safe and effective for de novo coronary lesions with good angiographic results at 9 months and similar clinical outcomes at 3 years compared to stent group.</description><identifier>ISSN: 1569-5794</identifier><identifier>EISSN: 1573-0743</identifier><identifier>EISSN: 1875-8312</identifier><identifier>DOI: 10.1007/s10554-019-01707-5</identifier><identifier>PMID: 31598811</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject><![CDATA[Adenosine ; Aged ; Angioplasty ; Angioplasty, Balloon, Coronary - adverse effects ; Angioplasty, Balloon, Coronary - instrumentation ; Balloon treatment ; Blood vessels ; Cardiac & Cardiovascular Systems ; Cardiac Catheterization ; Cardiac Catheters ; Cardiac Imaging ; Cardiology ; Cardiovascular Agents - administration & dosage ; Cardiovascular Agents - adverse effects ; Cardiovascular System & Cardiology ; Coated Materials, Biocompatible ; Coronary Angiography ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - physiopathology ; Coronary Artery Disease - therapy ; Coronary Restenosis - diagnostic imaging ; Coronary Restenosis - etiology ; Coronary Stenosis - diagnosis ; Coronary Stenosis - physiopathology ; Coronary Stenosis - therapy ; Equipment Design ; Female ; Fractional Flow Reserve, Myocardial ; Humans ; Imaging ; Implantation ; Implants ; Lesions ; Life Sciences & Biomedicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Paper ; Paclitaxel ; Paclitaxel - administration & dosage ; Paclitaxel - adverse effects ; PCB ; PCB compounds ; Polychlorinated biphenyls ; Predictive Value of Tests ; Radiology ; Radiology, Nuclear Medicine & Medical Imaging ; Registries ; Science & Technology ; Severity of Illness Index ; Stents ; Surgical implants ; Time Factors ; Treatment Outcome]]></subject><ispartof>INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2020-02, Vol.36 (2), p.179-185</ispartof><rights>Springer Nature B.V. 2019</rights><rights>The International Journal of Cardiovascular Imaging is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>6</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000513217200002</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c375t-bad01641fd678601bdd52c0fb75b9ff339b3117759f326a388a46f77d40769ce3</citedby><cites>FETCH-LOGICAL-c375t-bad01641fd678601bdd52c0fb75b9ff339b3117759f326a388a46f77d40769ce3</cites><orcidid>0000-0002-9169-6968</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10554-019-01707-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10554-019-01707-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,28253,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31598811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, Ju-Hyun</creatorcontrib><creatorcontrib>Shin, Eun-Seok</creatorcontrib><creatorcontrib>Her, Ae-Young</creatorcontrib><creatorcontrib>Lee, Joo Myung</creatorcontrib><creatorcontrib>Doh, Joon-Hyung</creatorcontrib><creatorcontrib>Nam, Chang-Wook</creatorcontrib><creatorcontrib>Koo, Bon-Kwon</creatorcontrib><title>Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions</title><title>INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING</title><addtitle>Int J Cardiovasc Imaging</addtitle><addtitle>INT J CARDIOVAS IMAG</addtitle><addtitle>Int J Cardiovasc Imaging</addtitle><description>Paclitaxel-coated balloon (PCB) treatment guided by fractional flow reserve (FFR) is safe and effective for de novo coronary lesions. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR in de novo lesion treatment with PCB. Baseline, post-balloon and 9-month angiographical parameters were obtained from 116 lesions of 104 patients. The cutoff value of iFR after balloon angioplasty used to define functionally nonsignificant residual stenotic lesions was 0.86 and they were subdivided into PCB or Stent group according to the treated device. The primary endpoint was late lumen loss at 9 months and the secondary endpoint was target vessel failure (TVF) at 3 years. Fifty-eight lesions were treated with PCB only and 58 lesions were treated with metal stent implantation. There were no differences in iFR between PCB and Stent groups at baseline (0.76 ± 0.19 vs. 0.73 ± 0.23, p = 0.630) and after procedure (0.93 ± 0.04 vs. 0.94 ± 0.05, p = 0.574). At 9 months, late lumen loss was significantly lower in PCB group compared with Stent group (0.04 ± 0.32 mm vs. 0.59 ± 0.77 mm, p = 0.001). At 3-year follow-up, TVF were not different between the treatment groups (5.2% vs. 8.6%, p = 0.453). PCB treatment guided by iFR measured right after balloon angioplasty is safe and effective for de novo coronary lesions with good angiographic results at 9 months and similar clinical outcomes at 3 years compared to stent group.</description><subject>Adenosine</subject><subject>Aged</subject><subject>Angioplasty</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>Angioplasty, Balloon, Coronary - instrumentation</subject><subject>Balloon treatment</subject><subject>Blood vessels</subject><subject>Cardiac & Cardiovascular Systems</subject><subject>Cardiac Catheterization</subject><subject>Cardiac Catheters</subject><subject>Cardiac Imaging</subject><subject>Cardiology</subject><subject>Cardiovascular Agents - administration & dosage</subject><subject>Cardiovascular Agents - adverse effects</subject><subject>Cardiovascular System & Cardiology</subject><subject>Coated Materials, Biocompatible</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Disease - diagnosis</subject><subject>Coronary Artery Disease - physiopathology</subject><subject>Coronary Artery Disease - therapy</subject><subject>Coronary Restenosis - diagnostic imaging</subject><subject>Coronary Restenosis - etiology</subject><subject>Coronary Stenosis - diagnosis</subject><subject>Coronary Stenosis - physiopathology</subject><subject>Coronary Stenosis - therapy</subject><subject>Equipment Design</subject><subject>Female</subject><subject>Fractional Flow Reserve, Myocardial</subject><subject>Humans</subject><subject>Imaging</subject><subject>Implantation</subject><subject>Implants</subject><subject>Lesions</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - adverse effects</subject><subject>PCB</subject><subject>PCB compounds</subject><subject>Polychlorinated biphenyls</subject><subject>Predictive Value of Tests</subject><subject>Radiology</subject><subject>Radiology, Nuclear Medicine & Medical Imaging</subject><subject>Registries</subject><subject>Science & Technology</subject><subject>Severity of Illness Index</subject><subject>Stents</subject><subject>Surgical implants</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1569-5794</issn><issn>1573-0743</issn><issn>1875-8312</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkV2L1TAQhoMo7of-AS-k4I2wRGeSpmkv5eDHwoI3eh3SdLJ06UmOSbqr_94cu67ghQgJCeF5h5k8jL1AeIMA-m1GUKrlgEPdGjRXj9gpKi056FY-Pt67gSs9tCfsLOcbABAg5FN2IlENfY94yugy5GJDXRTX3NzZW-I-ETXJljny63WeaGoO1i1zsd9p4S7aUl9GuywxhqYksmVPoTQ-pmaiJsTb2LiYYrDpR7NQnmPIz9gTb5dMz-_Pc_b1w_svu0_86vPHy927K-6kVoWPdgLsWvRTp_sOcJwmJRz4Uatx8F7KYZSIWqvBS9FZ2fe27bzWUwu6GxzJc_Z6q3tI8dtKuZj9nB0tyzaeERKkbpUSWNFXf6E3cU2hdlcp1XYoAUWlxEa5FHNO5M0hzfs6mUEwRwlmk2CqBPNLglE19PK-9DruaXqI_P71ClxswB2N0Wc3U3D0gFVNCqVALeBorNL9_9O7qqmKC7u4hlKjcovmiodrSn-G_Ef_PwEDVbMG</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Chung, Ju-Hyun</creator><creator>Shin, Eun-Seok</creator><creator>Her, Ae-Young</creator><creator>Lee, Joo Myung</creator><creator>Doh, Joon-Hyung</creator><creator>Nam, Chang-Wook</creator><creator>Koo, Bon-Kwon</creator><general>Springer Netherlands</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9169-6968</orcidid></search><sort><creationdate>20200201</creationdate><title>Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions</title><author>Chung, Ju-Hyun ; Shin, Eun-Seok ; Her, Ae-Young ; Lee, Joo Myung ; Doh, Joon-Hyung ; Nam, Chang-Wook ; Koo, Bon-Kwon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-bad01641fd678601bdd52c0fb75b9ff339b3117759f326a388a46f77d40769ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine</topic><topic>Aged</topic><topic>Angioplasty</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>Angioplasty, Balloon, Coronary - instrumentation</topic><topic>Balloon treatment</topic><topic>Blood vessels</topic><topic>Cardiac & Cardiovascular Systems</topic><topic>Cardiac Catheterization</topic><topic>Cardiac Catheters</topic><topic>Cardiac Imaging</topic><topic>Cardiology</topic><topic>Cardiovascular Agents - administration & dosage</topic><topic>Cardiovascular Agents - adverse effects</topic><topic>Cardiovascular System & Cardiology</topic><topic>Coated Materials, Biocompatible</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Disease - diagnosis</topic><topic>Coronary Artery Disease - physiopathology</topic><topic>Coronary Artery Disease - therapy</topic><topic>Coronary Restenosis - diagnostic imaging</topic><topic>Coronary Restenosis - etiology</topic><topic>Coronary Stenosis - diagnosis</topic><topic>Coronary Stenosis - physiopathology</topic><topic>Coronary Stenosis - therapy</topic><topic>Equipment Design</topic><topic>Female</topic><topic>Fractional Flow Reserve, Myocardial</topic><topic>Humans</topic><topic>Imaging</topic><topic>Implantation</topic><topic>Implants</topic><topic>Lesions</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - adverse effects</topic><topic>PCB</topic><topic>PCB compounds</topic><topic>Polychlorinated biphenyls</topic><topic>Predictive Value of Tests</topic><topic>Radiology</topic><topic>Radiology, Nuclear Medicine & Medical Imaging</topic><topic>Registries</topic><topic>Science & Technology</topic><topic>Severity of Illness Index</topic><topic>Stents</topic><topic>Surgical implants</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, Ju-Hyun</creatorcontrib><creatorcontrib>Shin, Eun-Seok</creatorcontrib><creatorcontrib>Her, Ae-Young</creatorcontrib><creatorcontrib>Lee, Joo Myung</creatorcontrib><creatorcontrib>Doh, Joon-Hyung</creatorcontrib><creatorcontrib>Nam, Chang-Wook</creatorcontrib><creatorcontrib>Koo, Bon-Kwon</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, Ju-Hyun</au><au>Shin, Eun-Seok</au><au>Her, Ae-Young</au><au>Lee, Joo Myung</au><au>Doh, Joon-Hyung</au><au>Nam, Chang-Wook</au><au>Koo, Bon-Kwon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions</atitle><jtitle>INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING</jtitle><stitle>Int J Cardiovasc Imaging</stitle><stitle>INT J CARDIOVAS IMAG</stitle><addtitle>Int J Cardiovasc Imaging</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>36</volume><issue>2</issue><spage>179</spage><epage>185</epage><pages>179-185</pages><issn>1569-5794</issn><eissn>1573-0743</eissn><eissn>1875-8312</eissn><abstract>Paclitaxel-coated balloon (PCB) treatment guided by fractional flow reserve (FFR) is safe and effective for de novo coronary lesions. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR in de novo lesion treatment with PCB. Baseline, post-balloon and 9-month angiographical parameters were obtained from 116 lesions of 104 patients. The cutoff value of iFR after balloon angioplasty used to define functionally nonsignificant residual stenotic lesions was 0.86 and they were subdivided into PCB or Stent group according to the treated device. The primary endpoint was late lumen loss at 9 months and the secondary endpoint was target vessel failure (TVF) at 3 years. Fifty-eight lesions were treated with PCB only and 58 lesions were treated with metal stent implantation. There were no differences in iFR between PCB and Stent groups at baseline (0.76 ± 0.19 vs. 0.73 ± 0.23, p = 0.630) and after procedure (0.93 ± 0.04 vs. 0.94 ± 0.05, p = 0.574). At 9 months, late lumen loss was significantly lower in PCB group compared with Stent group (0.04 ± 0.32 mm vs. 0.59 ± 0.77 mm, p = 0.001). At 3-year follow-up, TVF were not different between the treatment groups (5.2% vs. 8.6%, p = 0.453). PCB treatment guided by iFR measured right after balloon angioplasty is safe and effective for de novo coronary lesions with good angiographic results at 9 months and similar clinical outcomes at 3 years compared to stent group.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>31598811</pmid><doi>10.1007/s10554-019-01707-5</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9169-6968</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1569-5794 |
ispartof | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2020-02, Vol.36 (2), p.179-185 |
issn | 1569-5794 1573-0743 1875-8312 |
language | eng |
recordid | cdi_pubmed_primary_31598811 |
source | MEDLINE; SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
subjects | Adenosine Aged Angioplasty Angioplasty, Balloon, Coronary - adverse effects Angioplasty, Balloon, Coronary - instrumentation Balloon treatment Blood vessels Cardiac & Cardiovascular Systems Cardiac Catheterization Cardiac Catheters Cardiac Imaging Cardiology Cardiovascular Agents - administration & dosage Cardiovascular Agents - adverse effects Cardiovascular System & Cardiology Coated Materials, Biocompatible Coronary Angiography Coronary Artery Disease - diagnosis Coronary Artery Disease - physiopathology Coronary Artery Disease - therapy Coronary Restenosis - diagnostic imaging Coronary Restenosis - etiology Coronary Stenosis - diagnosis Coronary Stenosis - physiopathology Coronary Stenosis - therapy Equipment Design Female Fractional Flow Reserve, Myocardial Humans Imaging Implantation Implants Lesions Life Sciences & Biomedicine Male Medicine Medicine & Public Health Middle Aged Original Paper Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects PCB PCB compounds Polychlorinated biphenyls Predictive Value of Tests Radiology Radiology, Nuclear Medicine & Medical Imaging Registries Science & Technology Severity of Illness Index Stents Surgical implants Time Factors Treatment Outcome |
title | Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T13%3A38%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Instantaneous%20wave-free%20ratio-guided%20paclitaxel-coated%20balloon%20treatment%20for%20de%20novo%20coronary%20lesions&rft.jtitle=INTERNATIONAL%20JOURNAL%20OF%20CARDIOVASCULAR%20IMAGING&rft.au=Chung,%20Ju-Hyun&rft.date=2020-02-01&rft.volume=36&rft.issue=2&rft.spage=179&rft.epage=185&rft.pages=179-185&rft.issn=1569-5794&rft.eissn=1573-0743&rft_id=info:doi/10.1007/s10554-019-01707-5&rft_dat=%3Cproquest_pubme%3E2303745521%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2354613012&rft_id=info:pmid/31598811&rfr_iscdi=true |